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Objectives: To determine delirium occurrence rate, duration, and sever-
ity in patients admitted to the ICU with coronavirus disease 2019.
Design: Retrospective data extraction study from March 1, 2020, to 
June 7, 2020. Delirium outcomes were assessed for up to the first 14 
days in ICU.
Setting: Two large, academic centers serving the state of Indiana.
Patients: Consecutive patients admitted to the ICU with positive 
severe acute respiratory syndrome coronavirus 2 nasopharyngeal 
swab polymerase chain reaction test from March 1, 2020, to June 
7, 2020, were included. Individuals younger than 18 years of age, 
without any delirium assessments, or without discharge disposition 
were excluded.
Measurements and Main Results: Primary outcomes were delir-
ium rates and duration, and the secondary outcome was delir-
ium severity. Two-hundred sixty-eight consecutive patients were 
included in the analysis with a mean age of 58.4 years (sd, 
15.6 yr), 40.3% were female, 44.4% African American, 20.7% 
Hispanic, and a median Acute Physiology and Chronic Health 
Evaluation II score of 18 (interquartile range, 13–25). Delirium 
without coma occurred in 29.1% of patients, delirium prior 
to coma in 27.9%, and delirium after coma in 23.1%. The first 
Confusion Assessment Method for the ICU assessment was posi-
tive for delirium in 61.9%. Hypoactive delirium was the most com-
mon subtype (87.4%). By day 14, the median number of delirium/
coma-free were 5 days (interquartile range, 4–11 d), and median 
Confusion Assessment Method for the ICU-7 score was 6.5 (inter-
quartile range, 5–7) indicating severe delirium. Benzodiazepines 
were ordered for 78.4% of patients in the cohort. Mechanical ven-
tilation was associated with greater odds of developing delirium 
(odds ratio, 5.0; 95% CI, 1.1–22.2; p = 0.033) even after adjust-
ing for sedative medications. There were no between-group dif-
ferences in mortality.
Conclusions: Delirium without coma occurred in 29.1% of patients 
admitted to the ICU. Delirium persisted for a median of 5 days and 
was severe. Mechanical ventilation was significantly associated with 
odds of delirium even after adjustment for sedatives. Clinical attention 
to manage delirium duration and severity, and deeper understanding 
of the virus’ neurologic effects is needed for patients with coronavirus 
disease 2019.
Key Words: brain diseases; coma; coronavirus disease 2019; critical 
illness; delirium; respiratory insufficiency
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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or novel coronavirus disease 2019 (COVID-19) has emerged as a global pandemic and is associated with 
rapid spread, severe respiratory failure, and significant morbidity 
and mortality (1, 2). As clinical experience with COVID-19 grows, 
neurologic manifestations of the disease are receiving increased 
attention. A recently published small case series from France 
reported delirium occurred in 26 of 40 patients (65%) admitted to 
the ICU with COVID-19 (3). However, the duration and severity 
of delirium in critically ill COVID-19 patients have not been well 
described.
Delirium is a serious neurologic syndrome independently asso-
ciated with longer duration of mechanical ventilation, prolonged 
ICU and hospital stays, increased mortality, and institutionaliza-
tion after discharge (4–8). Increasing levels of delirium severity 
and duration amplify these outcomes and are independently asso-
ciated with worsening cognitive and functional outcomes post 
discharge (9–12). Prior to COVID-19, the prevalence of delirium 
in mechanically ventilated patients has been decreasing from a 
historically high rate of 80% to a range of 16.5–33% (13–19). In 
the setting of the current global health crisis, hospital resources 
have been stretched to their limits to meet the needs of a large 
number of critically ill patients. The unintended impact of lim-
ited resources on clinical practice has raised concerns that current 
ICU delirium rates have returned to the historically high levels 
(20–22). As of August 9, 2020, there are over 5 million confirmed 
COVID-19 cases in the United States and approximately 12% 
of COVID-19 patients required ICU level care (1, 2, 23). In this 
context, delirium is likely to pose a long-term public health chal-
lenge if rates in the United States are as high as recently reported 
in France.
Therefore, we conducted this study at two large academic health 
systems in the urban Midwest to measure incidence of delirium, 
delirium duration, and delirium severity and investigate risk fac-
tors associated with delirium in critically ill patients admitted with 
COVID-19.
MATERIALS AND METHODS
The observational, retrospective data extraction study was con-
ducted at two large, urban, academic, level I trauma centers 
(Indiana University Health Methodist Hospital and Eskenazi 
Health) serving as major referral hospitals for the state of Indiana 
and affiliated with Indiana University School of Medicine 
(Indianapolis, Indiana). Methodist Hospital is an 802-bed qua-
ternary care referral center with an average of 150 ICU admis-
sions per month. Eskenazi Health is a 336-bed safety net hospital 
with an average of 120 ICU admissions per month. The study 
received ethical approval from the Institutional Review Board at 
Indiana University (April 17, 2020, categorized as exempt, num-
ber 2004316653). All consecutive patients admitted to the ICUs 
of Methodist Hospital and Eskenazi Health with a positive result 
by SARS-CoV-2 nasopharyngeal swab polymerase chain reac-
tion test from March 1, 2020, to June 7, 2020, were included in 
the electronic health record data abstraction. Exclusion criteria 
were as follows: patients under the age of 18, admitted after June 
7, 2020, patients with no delirium assessments recorded in the 
electronic medical record for the duration of the follow-up period, 
and patients remaining admitted at the end of the study follow-up 
period (i.e., August 8, 2020).
Exposures and Outcomes
The main exposure variables were patients’ demographics, comor-
bidities, laboratory results, and severity of illness at admission. The 
primary outcomes were rate of delirium and delirium/coma dura-
tion during the first 14 days of admission to the ICU. Delirium/
coma duration was defined by the number of days the patient 
was alive and free from delirium or coma by day 14. Patients 
who were discharged from the ICU prior to 14 days did not have 
subsequent delirium or coma assessments performed outside the 
ICU. Coma was assessed using the Richmond Agitation-Sedation 
Scale (RASS) and delirium was identified through the Confusion 
Assessment Method for the ICU (CAM-ICU). Coma was defined 
as a RASS score of –4 or –5, making patients ineligible for a CAM-
ICU screening, while patients with a RASS score of –3 or greater 
were eligible for a CAM-ICU assessment (24, 25). The CAM-
ICU score was determined by examining the patient for 1) acute 
or fluctuating changes in mental status, 2) inattention, 3) altered 
level of consciousness, and 4) disorganized thinking. Patients 
were considered delirious if they displayed acute or fluctuating 
changes in mental status and inattention, plus altered level of con-
sciousness, and/or disorganized thinking on the CAM-ICU. ICU 
nurses administered the RASS and CAM-ICU bid (around 07:00 
to 08:00, and then between 19:00 and 20:00) to measure level of 
consciousness and delirium, respectively. These standardized and 
validated screening tools were implemented in our healthcare 
systems in 2011 and are normally obtained throughout the ICU 
stay. Hyperactive delirium was defined as a RASS score of +1 to 
+4 at the time of positive CAM-ICU, and hypoactive delirium was 
defined as a RASS score –3 to 0 with a positive CAM-ICU score. 
The secondary outcome of delirium severity was assessed using 
the CAM-ICU-7, which requires all components of the CAM-ICU 
to be assessed for each patient rather than a dichotomous CAM-
ICU positive or negative result. The CAM-ICU-7 was imple-
mented into the electronic medical record at Eskenazi Health in 
2017 and is assessed bid in the subset of patients receiving care at 
this hospital site. CAM-ICU-7 scores range from 0 to 7, with 0–2 
indicating no delirium, 3–5 mild to moderate delirium, and 6–7 
as severe delirium (12).
Data Collection
Research assistants familiar with electronic medical systems at the 
hospitals (Cerner PowerChart, Epic Health Systems) retrospec-
tively abstracted study data from the medical record, including 
CAM-ICU assessments performed by clinical nurses, and results 
were entered directly into an electronic Research Electronic 
Data Capture database. Data obtained from the medical record 
included patient demographics (age, gender, self-reported race), 
insurance status, comorbidities, vital signs, laboratory and imag-
ing results (within 24 hr of ICU admission), level of consciousness 
(RASS), date/time, and results of delirium assessments for up to 
the first 14 days of ICU stay (overall CAM-ICU positive or nega-
tive, including CAM-ICU features as applicable: altered mental 
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status, disorganized thinking, altered level of consciousness, dis-
organized thinking, and CAM-ICU-7 scores), SARS-CoV-2 test 
results, medication orders, and dates of admission and discharge 
from hospital and ICU. Date of death during the hospitalization 
was also recorded including level of care at time of death (ICU vs 
non-ICU). Comorbidities are presented as Charlson Comorbidity 
Index using diagnoses lists documented in the medical record. 
Acute Physiology and Chronic Health Evaluation II (APACHE II) 
score was calculated using laboratory values, vital signs, and neu-
rologic assessments from first 24 hours of ICU admission.
Statistical Analysis
Demographic and clinical characteristics were compared between 
patients who had delirium positive and those without delirium 
using two-sample t tests (normal data) and Wilcoxon rank-sum 
tests (skewed data) for continuous outcomes or Fisher exact test 
for categorical variables. Summary statistics, including median 
and interquartile range (IQR), were provided for patients with 
delirium. Logistic regression was used including demographic or 
clinical characteristics that were significantly different between 
patients with delirium and those without delirium as independent 
variables to identify factors associated with delirium.
RESULTS
A total of 301 consecutive patients with COVID-19 were admit-
ted from March 1, 2020, to June 7, 2020, to the ICUs at the two 
hospital systems. We excluded 33 patients, 32 did not have any 
delirium assessments and one remained admitted at the end of the 
follow-up period (eFig. 1, Supplemental Digital Content, http://
links.lww.com/CCX/A439). In total, 268 patients comprised 
the study cohort. Demographics and clinical characteristics for 
the cohort are presented in Table 1 and eTable 1 (Supplemental 
Digital Content, http://links.lww.com/CCX/A439). The mean 
age of the cohort was 58.4 years (sd, 15.6 yr), 40.3% were female, 
44.4% African American, and 20.7% Hispanic, 27.3% used com-
mercial insurance, and 23.2% Medicare. The median Charlson 
Comorbidity Index score was 1 (IQR, 0–2), with hypertension 
(60.1%), obesity (57.5%), tobacco use (25.7%), and chronic lung 
disease (20.9%) the most frequent comorbid conditions. The 
median APACHE II score was 18 (IQR, 13–25), and 80.2% of 
patients in the cohort underwent invasive mechanical ventilation. 
Cerebrovascular accident (ischemic or hemorrhagic) was identi-
fied in seven of 268 patients.
Delirium in Critically Ill Patients With COVID-19
Delirium without coma occurred in 29.1% (78/268), delirium 
prior to coma in 27.9% (75/268), and delirium after coma in 23.1% 
(62/268) of the cohort. In patients with delirium, 61.9% (133/215) 
were positive on the first CAM-ICU assessment. As shown in 
Table  1, patients with delirium had higher median APACHE 
II severity of illness scores (20, IQR 15–26 vs 11.0, IQR 9–16; 
p < 0.001) and were more likely to be mechanically ventilated 
(93.5% vs 26.4%; p < 0.001) than patients without delirium. There 
were lower Pao2:Fio2 ratios (81.8, IQR 62–121 vs 103.1, IQR 91.7–
185.7; p = 0.001) and lower Glasgow Coma Scale scores (9.0, IQR 
6.0–14.0 vs 15.0, IQR 14–15.0; p < 0.001) in patients with delirium 
during the first 24 hours of ICU admission compared with those 
without delirium. Decreased level of consciousness was found in 
patients with delirium (median RASS score: –2.0, IQR–2.8 to –1.0 
vs 0, IQR 0–0) compared with those without delirium (Table 1).
Delirium Duration, Subtypes of Delirium, and Delirium 
Severity
As shown in Table 2, patients in the cohort had median 5 (IQR, 
2–9) delirium/coma-free days by day 14 with median delirium 
duration of 5 days (IQR, 2–8 d). Patients had a median RASS of –2 
(IQR, –3 to 0) at the time of ICU admission indicating light seda-
tion. Figure 1 shows the daily rates of patient’s delirium, coma, or 
delirium/coma-free status for up to 14 days of ICU admission. In 
our study, hypoactive delirium occurred in 87.4% of patients on 
the first CAM-ICU assessment, and the median duration of hypo-
active delirium was 4 days (IQR, 2–6 d). Details of the subtypes of 
delirium for the entire cohort are shown in Table 2 and Figure 2. 
In the subset of patients with delirium severity assessments 
(n = 134), the median CAM-ICU-7 score was 6.5 (IQR, 5–7) rep-
resenting severe delirium.
Factors Associated With Delirium
Patients with delirium had greater mechanical ventilation days 
(median 9.1 d, IQR 4.6–14.0 vs 0, IQR 0–0.2; p < 0.001) and ICU 
days (median 14.4, IQR 9.2–19.5 vs 4.0, IQR 2.2–6.8; p < 0.001) 
compared with patients without delirium (Table 3). We did not 
find a significant difference in hospital mortality between patients 
with delirium compared with those without (23.3% vs 15.1%; 
p = 0.264), as shown in Table 3. Sedative medication orders for 
the study cohort are shown in Table 4. Patients with delirium had 
greater frequency of orders for benzodiazepines (86.5% vs 45.3%; 
p < 0.001), opioids (94.4% vs 50.9%; p < 0.001), propofol (83.3% 
vs 24.5%; p < 0.001), and dexmedetomidine (34.9% vs 5.7%; 
p < 0.001) compared with patients without delirium. Frequency of 
antipsychotics and other sedatives used during the pandemic are 
shown in Table 4. Daily rates of patient’s discharge from ICU and 
death over the first 14 days are shown in eFigure 2 (Supplemental 
Digital Content, http://links.lww.com/CCX/A439). In the logistic 
regression model consisting of age, receipt of mechanical ventila-
tion, APACHE II scores, Glasgow Coma Scale RASS, and sedative 
medications, only mechanical ventilation was significantly asso-
ciated with greater odds of developing delirium (odds ratio, 5.0; 
95% CI, 1.1–22.2; p = 0.033).
DISCUSSION
In this retrospective study of COVID-19 patients admitted to 
the ICU at two large hospitals, nearly 29% experienced delirium 
without coma, nearly 28% developed delirium before coma, while 
approximately 23% had delirium after coma. Delirium occurred 
early in the ICU course (within the first 2 d) and persisted for 
median length of 5 days. In addition, patients with COVID-19 
experienced severe delirium, and invasive mechanical ventila-
tion was associated with a marked increase in odds of delirium. 
While mortality rates did not statistically differ by delirium status 
likely due to the small sample size of patients without delirium, 
we found mortality to be 8% higher in patients with delirium. 
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TABLE 1. Characteristics of Critically Ill Patients Admitted With Coronavirus Disease 2019 (n = 268)
Demographic/Clinical Characteristic Total (n = 268)
Delirium Positivea  
(n = 215)
Delirium Negativea  
(n = 53) p
Age, mean (sd) 58.4 (15.6) 59.4 (15.0) 54.3 (17.3) 0.034
Age, stratified, n (%)    0.053
 18–49 77 (28.7) 57 (26.5) 20 (37.7)  
 50–64 88 (32.8) 68 (31.6) 20 (37.7)  
 65+ 103 (38.4) 90 (41.9) 13 (24.5)  
Sex, n (%)
 Female 108 (40.3) 90 (41.9) 18 (34.0) 0.349
Race, n (%) 0.499
 African American 118 (44.4) 93 (43.7) 25 (47.2)
 Caucasian 76 (28.6) 59 (27.7) 17 (32.1)  
 Hispanic 55 (20.7) 45 (21.1) 10 (18.9)  
 Other 17 (6.4) 16 (7.5) 1 (1.9)  
Insurance, n (%) 0.176
 Medicare 62 (23.2) 50 (23.4) 12 (22.6)
 Medicaid 45 (16.9) 40 (18.7) 5 (9.4)  
 Medicare and Medicaid 34 (12.7) 30 (14.0) 4 (7.5)  
 Commercial 73 (27.3) 54 (25.2) 19 (35.8)  
 Self-pay 33 (12.4) 23 (10.7) 10 (18.9)  
 Other 20 (7.5) 17 (7.9) 3 (5.7)  
Comorbidities, n (%)
 Hypertension 161 (60.1) 133 (61.9) 28 (52.8) 0.273
 Diabetes 111 (41.4) 89 (41.4) 22 (41.5) 1.000
 Obesity, body mass index (calculated with  
height and weight at admission) > 30
142 (57.5) 114 (57.3) 28 (58.3) 1.000
 Tobacco use 69 (25.7) 55 (25.6) 14 (26.4) 1.000
 Chronic obstructive pulmonary disease or asthma 56 (20.9) 45 (20.9) 11 (20.8) 1.000
 Chronic kidney diseaseb 42 (15.7) 37 (17.2) 5 (9.4) 0.207
 Chronic heart failure 34 (12.7) 27 (12.6) 7 (13.2) 1.000
 Cardiac artery disease 30 (11.2) 27 (12.6) 3 (5.7) 0.223
 Dementia 9 (3.4) 0 (0.0) 9 (4.2) 0.212
Charlson Comorbidity Index 1.0 (0.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–1.0) 0.407
Acute Physiology and Chronic Health Evaluation IIc 18.0 (13.0–25.0) 20.0 (15.0–26.0) 11.0 (9.0–16.0) < 0.001
Laboratory values, clinical and respiratory characteristics, median (interquartile range) or n (%)d  
 WBC count × 109/L 9.0 (6.5–12.7) 9.4 (6.5–13.3) 7.5 (6.5–10.0) 0.067
 Glasgow Coma Scale (0–15)c 10.0 (6.0–15.0) 9.0 (6.0–14.0) 15.0 (14.0–15.0) < 0.001
 Richmond Agitation-Sedation Scale (14 d)c,e –1.5 (–2.5 to –0.3) –2.0 (–2.8 to –1.0) 0.0 (0.0–0.0) < 0.001
 Pao2, mm Hg 70.0 (56.0–89.0) 69.5 (56.5–89.0) 73.5 (53.0–85.0) 0.959
 Pao2:Fio2 ratio
c 87.0 (64.0–127.8) 81.8 (62.0–121.0) 103.1 (91.7–185.7) 0.001
 Invasive mechanical ventilationc 215 (80.2) 201 (93.5) 14 (26.4) < 0.001
 Presence of shock 47 (17.5) 45 (20.9) 2 (3.8) 0.002
aDelirium status determined by a positive Confusion Assessment Method for the ICU clinical assessment.
bChronic kidney disease includes end-stage renal disease.
cSeverity of illness, Glasgow Coma Scale, Pao2:Fio2, Richmond Agitation-Sedation Scale (RASS) scores, and percent mechanically ventilated were significantly different 
(p < 0.05) between groups (no delirium/delirium) in univariate analysis.
dLaboratory values, clinical, respiratory characteristics, and severity of illness measurements represent data from first 24 hr of ICU admission.
eRASS scores were calculated using scores for up to the first 14 d of ICU admission.
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To the best of our knowledge, our study is the first to describe 
delirium rates, duration, and severity in critically ill patients with 
COVID-19 using standardized delirium assessment tools. Due to 
the increased risk of mortality and morbidity following delirium, 
including the development of long-term cognitive impairment 
and post intensive care syndrome, this study has important impli-
cations for clinical practice, the recovery of patients with COVID-
19 admitted to intensive care, public health decision making, and 
even future research priorities (26, 27).
Our study findings represent a departure from our own cen-
ter’s recently reported rates of ICU delirium (22.7%) and rates 
of mechanical ventilation (36%) during the influenza pandemic 
occurring in 2009–2010 (eTable 2, Supplemental Digital Content, 
http://links.lww.com/CCX/A439). Reductions in the prevalence 
of ICU delirium from a historical high of 80% to rates of 16.5–33% 
have been reported over the past 2 years (13, 16, 17, 19). These 
reductions were likely linked to the implementation of the Society 
of Critical Care Medicine’s Prevention and Management of Pain, 
Agitation/Sedation, Delirium, Immobility, and Sleep Disruption 
in the ICU guidelines, multidisciplinary bundled protocols for 
delirium prevention (ABCDEF), avoidance of deliriogenic agents, 
increasing use of noninvasive ventilation strategies and heated 
high-flow nasal cannula devices leading to reduced rates of inva-
sive ventilation, and increasing clinician awareness regarding the 
harms of delirium (17, 28–30). The COVID-19 crisis has seriously 
challenged these care improvements as preestablished multidisci-
plinary care models of ICU care become disrupted and health sys-
tems are overwhelmed with critically ill patients requiring invasive 
mechanical ventilation. Our study also emphasizes the increased 
use of benzodiazepines, opioids, and other sedative medications 
in the management of critically ill patients with COVID-19 at our 
center. While the high rates of hypoactive delirium found in our 
study cohort may be associated with sedative exposure or sever-
ity of illness, direct neurotoxicity of COVID-19 has also been 
proposed, including infiltration of the CNS leading to delirium 
(31–33). A recent meta-analysis on neuropsychiatric symptoms 
associated with severe coronavirus infections concluded that 
signs of delirium (confusion 27.9%, 95% CI, 20.5–36.0; impaired 
concentration or attention 38.2%, 95% CI, 29.0–47.9; and altered 
consciousness 20.7%, 95% CI, 12.6–30.3) were common in SARS 
and Middle East respiratory syndrome (34). Further, as recent 
studies have reported neurologic symptoms such as anosmia in 
COVID-19 and SARS-CoV-2 has been identified in cerebrospinal 
fluid as well as brain tissue, the neurotoxic impact of COVID-19 
is increasingly plausible (31–33, 35). Our study design does not 
permit exclusion of viral neurotoxicity as the cause of delirium or 
coma, and therefore, pathways for encephalopathy due to COVID-
19 require additional study.
While effective pharmacological therapies for treatment of 
COVID-19 as well as delirium are not yet available, our study 
sheds light on an alarming burden of delirium and coma in 
patients admitted to the ICU and the need for continued efforts 
on delirium prevention. Following and implementing evidence-
based ICU practices (such as the ABCDEF bundle) to minimize 
delirium occurrence and severity under the pandemic conditions 
will likely remain an ongoing challenge (30). The continued use of 
screening tools for delirium and delirium severity can also pro-
vide bedside clinicians with dynamic assessments to measure the 
impact of interventions in real-time (9, 12). As resources shrink 
in the face of the pandemic and the healthcare response disrupts, 
it is imperative to continue to follow and implement time-tested 
evidence-based practices. Finally, delirium in critically ill patients 
has been associated with long-term cognitive decline (10, 36). If 
other studies confirm higher rates of delirium in COVID-19 ICU 
patients, longitudinal follow-up will be crucial to understand the 
full impact of COVID-19 and understand the pathophysiology of 
COVID-19 related delirium.
Our study does have important limitations. This analysis is 
limited by its reliance on data from the medical record includ-
ing clinician-administered delirium assessments obtained when 
RASS of –3 to greater than +1 was present, leading to potentially 
false positive results. Data on the RASS score was extracted in 
TABLE 2. Clinical Outcomes in Critically Ill 
Patients Admitted With Coronavirus Disease 





Duration of delirium and coma, median (IQR)a
 Delirium/coma-free days by day 14 5 (2–9)
Duration of delirium, median (IQR) 5 (2–8)
Duration of coma, median (IQR) 1 (0–5)
Subtypes of delirium, n (%)
 Hypoactive delirium at first ICU assessmentb 188 (87.4)
 Hyperactive delirium at first ICU assessmentc 27 (12.6)
Duration of subtypes of delirium, median days (IQR)
 Hypoactive delirium duration days 4 (2–6)
 Hyperactive delirium duration days 0 (0–1)
Delirium severity, median (IQR)d
 Confusion Assessment Method for the ICU-7 
score
6.5 (5–7)
IQR = interquartile range.
aDelirium was defined as a positive Confusion Assessment Method for the ICU 
(CAM-ICU) assessment in the patient medical record for up to 14 d during their 
ICU coronavirus disease 2019 stay. Coma was defined by Richmond Agitation-
Sedation Scale (RASS) score of –4 or –5. Delirium/coma-free days: defined as 
number of days patient was alive and free of delirium or coma by day 14. Delirium 
was defined by CAM-ICU positive on either morning or afternoon assessment for 
up to 14 d while admitted to the ICU. Duration of coma was defined as number of 
days patient had coma by RASS score on either morning or afternoon assess-
ment for up to 14 d of ICU stay.
bHypoactive delirium was defined by RASS of –1 to –3 with positive CAM-ICU.
cHyperactive delirium was defined by a RASS score of +1 to +3 with positive 
CAM-ICU.
dDelirium severity was measured using the CAM-ICU-7 in 134 patients (0–7, 0–2: 
no delirium; 3–5: mild to moderate delirium; and 6–7: severe delirium).
Missing data: There were 2,861 possible days of delirium follow-up, and 2,257 
d had complete assessments. The remaining 604 d had incomplete assessment 
data as follows: 1) 157 d with no CAM or RASS (n = 98 patients) and 2) 447 d 
where RASS was other than –4 or –5, but CAM-ICU assessment was missing  
(n = 144). All patients had at least one RASS assessment and at least one CAM-
ICU assessment.
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Figure 2. Subtypes of delirium in critically ill patients with coronavirus disease 2019 (n = 268). Number above each bar column indicates number of patients 
assessed for delirium per day. Daily percentages do not equal 100% due to incomplete assessments, death, discharge from ICU, or screening negative for 
delirium. Number of patients screening positive for delirium per day: 65 (day 1), 92 (day 2), 87 (day 3), 98 (day 4), 93 (day 5), 93 (day 6), 99 (day 7), 95 (day 8), 
87 (day 9), 75 (day 10), 81 (day 11), 72 (day 12), 61 (day 13), and 63 (day 14). Confusion Assessment Method for the ICU (CAM-ICU) and Richmond Agitation-
Sedation Scale (RASS) assessments were performed up to bid while patient was admitted to the ICU. Hypoactive delirium was defined by RASS of –1 to –3 with 
positive CAM-ICU and hyperactive delirium was defined by a RASS score of +1 to +3 with positive CAM-ICU. Mixed delirium was defined as patients with both 
hyperactive and hypoactive delirium assessment on a given ICU day.
Figure 1. Daily rates of delirium, coma, or without delirium/coma status as assessed up to first 14 d of ICU stay (n = 268). Number above each bar column 
indicates number of patients assessed per day. Daily percentages do not equal 100% due to incomplete assessments, death, or discharge from ICU. Delirium 
was defined as a positive Confusion Assessment Method for the ICU (CAM-ICU) assessment on either morning or afternoon assessment. Coma was defined by 
Richmond Agitation-Sedation Scale (RASS) score of –4 or –5. Without delirium or coma was defined by RASS greater than –4 and a negative CAM-ICU on either 
morning or afternoon assessment.
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concordance with the delirium assessment; therefore, we were 
not able to provide a more global view of sedation depth, and 
patients may not have received consistent sedative interruption 
to provide more reliable delirium assessment. The limitation of 
clinician-administered delirium assessments has been minimized 
by the rigorous implementation and continued education on the 
CAM-ICU and CAM-ICU-7 at the participating institutions. 
While we included medication orders to estimate sedative expo-
sure, medication doses, frequency, and administration details 
were not available for the analysis. Additionally, adherence to the 
ABCDEF bundle at the patient level, as well as risk factors for 
delirium such as baseline cognitive and functional status, were 
not available. Our analysis is also limited to delirium and coma 
assessments performed in the first 14 days of ICU stay, and there-
fore, we are unable to describe the trajectory of delirium and coma 
for the duration of the hospitalization in this report. Together, 
these limitations preclude discrimination between sedative-asso-
ciated delirium and delirium secondary to neurotoxicity as a con-
sequence of COVID-19 infection. Strengths of the study include 
incorporation of delirium severity data, a racially and socioeco-
nomically diverse cohort of patients and protocolized delirium 
assessments conducted by bedside clinicians at two high volume 
and high acuity centers.
CONCLUSIONS
In our cohort of critically ill patients with COVID-19, delirium 
without coma occurred in 29.1%, delirium prior to coma in 27.9%, 
and delirium after coma in 23.1%. Delirium persisted for approxi-
mately 5 days and occurred at high severity. Invasive mechani-
cal ventilation is significantly associated with delirium even after 
adjustment for sedatives. Given these findings, continued atten-
tion to prevent and manage delirium, and a deeper understanding 
of the virus’ neurotoxic effects are critical.
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